Disease genetics: Decoded
Connect genetic variants to disease-driving genes, revealing hidden insights for faster, more precise drug discovery and target prioritisation.
Revolutionising Drug Discovery with 3D Multi-omics
Tap into a Wealth of Cellular Context
GenLink is powered by our 3D Multi-omic atlas – a rich omics data set of cell types and states across the human body. Powered by the Atlas – our platform delivers unparalleled depth to genomic analysis, empowering R&D teams to study mechanisms driving disease at a cellular level.
Decode hidden links in the DNA
Our platform can link GWAS variants (Single Nucleotide Polymorphisms) to affected genes in disease relevant cell types. It is engineered to detect distal, regulatory interactions between SNPs and gene promoters, extending beyond traditional eQTL analysis.
Access 3D Multi-Omic insights
Platform integrates 3D genomic analysis with several multi-omics data to offer unprecedented genome-scale visibility into regulatory effects.
Applications of GenLink Connect
Accelerated Target Discovery
Identify new and existing drug targets with precision using genetic and 3D Multi-omic evidence, speeding up target identification and prioritisation.
Indication-expansion Opportunities
Enable therapeutic opportunities by repurposing targets for new indications with precision, improving patient outcomes.
Evidence-based Target Validation
Add robust genetic evidence to strengthen the relevance of targets and uncover novel biology for new indications.
Reduce Risk with Data-driven Decisions
Base decisions on accurate, multi-dimensional evidence, at every stage of target discovery.
10x faster
novel target ID and prioritisation
6x greater
chance of identifying biologically relevant targets
Higher quality
targets for literature validation
Greater retention
of long-listed targets
Unlock the full potential of the human genome
Whether you’re exploring disease mechanisms, searching for novel drug targets, or delving into fundamental biology, GenLink provides the regulatory insights you need to drive your R&D forward.
